TaiMed Biologics Inc. (TPEX: 4147)
Taiwan
· Delayed Price · Currency is TWD 82.10
-0.40 (-0.48%)
Dec 20, 2024, 1:30 PM CST
TaiMed Biologics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -141.65 | -194.81 | -269.29 | -470.93 | -183.3 | -578.65 | Upgrade
|
| Depreciation & Amortization | 150.13 | 150.67 | 151.73 | 152.13 | 137.12 | 91.58 | Upgrade
|
| Other Amortization | 4.59 | 4.72 | 4.72 | 4.53 | 2.66 | 0.96 | Upgrade
|
| Loss (Gain) From Sale of Assets | 2.32 | - | - | 24.18 | 7.84 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | - | - | 10.62 | Upgrade
|
| Loss (Gain) From Sale of Investments | 3.17 | 29.05 | 122.81 | -26.76 | 63.13 | 213.09 | Upgrade
|
| Stock-Based Compensation | 25.27 | 10.51 | 12.27 | 10.22 | 16.68 | 27.38 | Upgrade
|
| Other Operating Activities | 18.45 | 5.82 | 168.85 | 101.38 | -15.5 | 37.35 | Upgrade
|
| Change in Accounts Receivable | 46.99 | -62.24 | 59.54 | 97.94 | -53.59 | -101.9 | Upgrade
|
| Change in Inventory | 196.57 | 110.85 | -382.84 | 14.84 | -384.99 | -538.72 | Upgrade
|
| Change in Accounts Payable | -22.55 | 13.41 | -122.49 | 116.79 | -130.24 | -13.69 | Upgrade
|
| Change in Unearned Revenue | -95.67 | -27.93 | -339.16 | 113.91 | 83.16 | 218.47 | Upgrade
|
| Change in Other Net Operating Assets | -30.88 | -65.64 | -11.33 | -349.5 | 255.09 | -21.8 | Upgrade
|
| Operating Cash Flow | 156.74 | -25.6 | -605.21 | -211.28 | -201.94 | -655.31 | Upgrade
|
| Capital Expenditures | -9.19 | -6.15 | -3.56 | -9.69 | -53.61 | -121.54 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | 0.41 | 2 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -11.3 | - | -1.21 | -3.87 | -332.16 | -16.29 | Upgrade
|
| Investment in Securities | -789.78 | -12.88 | 110.88 | 204.07 | 273.36 | 504.38 | Upgrade
|
| Other Investing Activities | -0.51 | 2.58 | - | - | 1.25 | 0.17 | Upgrade
|
| Investing Cash Flow | -810.76 | -16.46 | 106.12 | 190.92 | -109.16 | 366.71 | Upgrade
|
| Short-Term Debt Issued | - | - | 200 | - | - | - | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | 536 | - | Upgrade
|
| Total Debt Issued | - | - | 200 | - | 536 | - | Upgrade
|
| Long-Term Debt Repaid | - | -16.05 | -1.98 | -1.93 | -1.91 | -1.83 | Upgrade
|
| Net Debt Issued (Repaid) | -228.89 | -16.05 | 198.02 | -1.93 | 534.09 | -1.83 | Upgrade
|
| Issuance of Common Stock | 1,646 | 35.28 | 10.31 | 4.71 | 1.95 | 59.75 | Upgrade
|
| Other Financing Activities | -4.27 | - | 0.05 | 0.01 | - | - | Upgrade
|
| Financing Cash Flow | 1,413 | 19.23 | 208.38 | 2.79 | 536.04 | 57.92 | Upgrade
|
| Foreign Exchange Rate Adjustments | -3.28 | -0.28 | 13.21 | -2.9 | -5.78 | -2.48 | Upgrade
|
| Net Cash Flow | 755.58 | -23.1 | -277.51 | -20.47 | 219.16 | -233.16 | Upgrade
|
| Free Cash Flow | 147.55 | -31.75 | -608.77 | -220.96 | -255.55 | -776.86 | Upgrade
|
| Free Cash Flow Margin | 23.70% | -6.46% | -108.13% | -53.44% | -35.37% | -110.27% | Upgrade
|
| Free Cash Flow Per Share | 0.56 | -0.13 | -2.41 | -0.88 | -1.01 | -3.08 | Upgrade
|
| Cash Interest Paid | 13.32 | 14.76 | 9.88 | 7.44 | 3.84 | 0.35 | Upgrade
|
| Levered Free Cash Flow | 267.45 | 82.39 | -217.42 | -191.55 | -673.15 | -747.51 | Upgrade
|
| Unlevered Free Cash Flow | 275.71 | 91.65 | -211.11 | -186.9 | -670.59 | -747.29 | Upgrade
|
| Change in Net Working Capital | -210.1 | -35.8 | 255.15 | 36.24 | 358.31 | 485.62 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.